Platelet Interactions with Bacteria by Kerrigan, Steven W.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4
Platelet Interactions with Bacteria
Steven W.  Kerrigan
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/60531
1. Introduction
It is well established that the primary function of platelets is their adhesion to endotheli‐
um or to matrix protein components at sites of the injured vessel wall in the initiation of
haemostasis [1].Despite this critical role, platelets are poorly appreciated for their involve‐
ment in inflammatory or immune processes associated with host defence. The concept that
platelets interact with bacteria is  not new as there are many reports published through‐
out history describing this interaction. For example, the earliest report by Levaditi in 1901
demonstrated that platelets activated and ‘clumped’ when Vibrio cholerae were introduced
into the circulation of rabbits [2]. In 1931 Dudgeon demonstrated platelet clumping occurred
at 5 minutes of injecting S. aureus into rabbits [3]. More recently in the early 1970’s Clawson
and White demonstrated that bacteria were able to binding specifically to a platelet receptor,
triggering  a  signal  that  resulted  in  aggregation  and  degranulation  of  intracellular  con‐
tents [4-7]. These early studies provided observational evidence that platelets can respond
to invading pathogens.
As our knowledge of basic platelet biology developed in more modern times it has become
apparent  that  platelets  are  powerful  multifunctional  cells  that  are  involved in  processes
outside their traditional role of thrombosis and haemostasis. For example, platelets share
many similarities  with  professional  leukocytes  (white  blood cells)  well  characterised for
their role in immuno-protection following invasion by foreign invaders. Platelets can also
recognise foreign invaders through specific  receptors,  release their  granule contents  and
recruit immune cells.
Recently human platelets have been shown to express Toll Like Receptor (TLR) 1, 2, 4, 6, 8 and
9 [8-13]. These type I integral membrane receptors recognise common pathogen-associated
molecular patterns found in foreign invaders. Platelets also express Intracellular Cell Adhesion
Molecular (ICAM) 2 which binds to leukocyte β2 integrin, LFA-1 (α1β2, CD11a/CD18) and to
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dendritic cell specific ICAM grabbing nonintegrin (DC-SIGN). Trans interactions of platelet-
derived Junctional Adhesion Molecules (A and C) have been found to support the luminal
deposition of platelet chemokines and to enhance the recruitment of leukocytes. Upon
activation CD40L is upregulated on the platelet surface which results in stimulation of
endothelial cells through its cognate receptor CD40 and in increased expression of adhesion
molecules, release of chemokines (eg. RANTES) enhancing recruitment of leukocytes [14].
As a result of such receptor mediated interactions platelets can secrete granular contents which
have significant immuno-modulatory effects. Alpha granules contain proteins such as P-
selectin which mediates adhesion of platelets to monocytes, neutrophils and lymphocytes,
resulting in the formation of platelet leukocyte complexes [15-17]. Secretion also results in
release of many chemotactic agents which lead to the recruitment of various inflammatory
cells; platelet derived growth factor (PDGF) and 12-hydroxyeicosatetraenoic acid (12-HETE)
which recruit neutrophils [18, 19]; platelet factor 4 and platelet derived histamine releasing
factor (PDHRF) which recruit eosinophils in airway disease [20, 21]; PDGF and transforming
growth factor β (TGF-β) which recruit monocytes and macrophages and TGF-β which recruits
fibroblasts [22-24]. In addition the alpha granules also release many antimicrobial peptides
such as beta-lysin, platelet microbial protein (PMP), neutrophil activating peptide (NAP-2),
released upon activation normal T-cell expressed and secreted (RANTES) and fibrinopeptides
A and B [25-29].
2. Common observations in platelet-bacterial interactions
Unlike typical platelet agonists that bind to specific platelet receptors and trigger a response,
bacteria can interact with platelets using a number of different mechanisms.
Direct interaction: Bacteria express proteins that can directly interact with a surface receptor on
the platelet. In this case they have ligand-mimetic domains that act as agonists on the platelet
receptor. One such direct interaction is that with Streptococcus sanguinis which can directly to
GPIbα, the vWf receptor on the platelet [30]. Other potential mediators of platelet activation
are lipopolysaccharide (LPS) and lipoteichoic acid (LTA). LPS has been shown to activate
platelets and LTA has been shown to inhibit platelet activation [11, 31].
Indirect interaction (bridging protein): Bacteria can also coat itself in a plasma protein and then
use this mechanism as a bridge to its reciprocal platelet receptor. For example, Clumping factor
A & B [32] and fibronectin binding protein [33] on S. aureus can both bind fibronectin and/or
fibrinogen both of which are ligands for GPIIb/IIIa on the platelet. Helicobacter pylori can bind
vWf which interacts with GPIbα on the platelet [34]. The most common bridging molecule for
bacteria to use is IgG. IgG bound to the bacteria surface can interact with the platelet FcγRIIa
receptor and while it appears that this alone cannot stimulate platelet activation it acts in
conjunction with other bridging molecules [34-36]. In the absence of a second bridging
molecule bound antibody can trigger complement formation which can mediate platelet
activation via complement receptors in conjunction with the FcγRIIa receptor [36-38].
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Indirect interaction (secretion): Bacteria also have the potential to secrete products that can in
turn activate platelets. Porphyromonas gingivalis secretes gingipain, an enzyme that activates
the thrombin receptor on platelets which leads to platelet activation [39] and Escherichia coli
shiga toxin is associated with platelet activation [40] via a novel platelet glycosphingolipid [41]
Bacterial induced platelet aggregation is different in some respects to that seen with other
platelet agonists. Bacterial-induced aggregation is an all-or-nothing response, in that no matter
what concentration of bacteria are added to a platelet preparation the extent of aggregation
will always be maximal (often less than that seen with other agonists) or else there is no
aggregation. Unlike other agonists there is a lag time to aggregation. Adjusting the concen‐
tration of bacteria shortens the lag time to a minimum but never eliminates it. There are two
categories of bacteria: those that have a short lag time of around 2-5 mins e.g. S. aureus and
those with a long lag time of 15-20 mins e.g. S. sanguinis or S. gordonii. The short lag time usually
indicates the presence of a direct interaction and is dependent on the levels of expression of
the interacting protein on the bacterial surface [36]. The long lag time usually indicates a
complement –dependent aggregation process.
Bacteria can finally support platelet adhesion, induce platelet spreading or trigger platelet
aggregation and these interactions are often mediated by different platelet receptors and
bacterial proteins. For example, S. gordonii supports platelet adhesion via a GPIbα – Hsa/GspB
interaction, whereas platelet spreading is mediated by GPIIbIIIa –PadA interaction and finally
platelet aggregation is mediated by GPIbα – Hsa/GspB/SspA/B interaction.
3. Platelet receptors recognised by bacteria
3.1. Glycoprotein Ibα
3.1.1. Direct interaction with GPIbα
Streptococcus sanguinis and Streptococcus gordonii are common commensals found in the oral
cavity and have been found to bind directly to GPIbα. The interaction is mediated by a growing
family of bacteria adhesins called Serine Rich Repeat (SRR) proteins. Streptococcus sanguinis
expresses SrpA and Streptococcus gordonii expresses GspB and Hsa. [30, 42, 43]. The region on
GspB and Hsa that bind to GPIbα has been localised to the non-repetitive region and inter‐
estingly does not contain any sequence similarity with vWf [44]. The non-repetitive ligand
binding region of GspB has been worked out by crystallography studies as having a modular
organization: helical domain; a Siglec domain (domain that binds sialic acids); and a unique
domain [45]. A mammalian carbohydrate binding domain, identified as the Siglec domain,
was found in Hsa and SrpA but not in the protein sequences of five other characterised SRR
proteins on other bacteria suggesting that this domain is critical for the interaction with
GPIbα [45]. Consistent with this finding is that at present Hsa and SrpA are the only strepto‐
coccal SRR proteins that have been found to bind to GPIbα. Interestingly, a point mutation in
the Siglec domain at R484E showed a marked reduction in binding to purified GPIbα, in
addition use of this mutated streptococcus reduced vegetative growth in a rat model of
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infective endocarditis [45]. S. aureus is also a common commensal of the human found
predominately in the anterior nares of the nostrils and a opportunistic pathogen found in the
blood stream. This bacteria also expresses a highly glycosylated SRR protein named SraP on
its surface. A strain of Staphylococcus aureus deficient in expression of SraP led to the reduced
virulence in a rabbit model of endocarditis [46]. Regardless of the fact that SraP shares
significant similarities with a number of other SRR’s found in the streptococci that have been
found to bind to platelet GPIbα, it is currently unclear as to whether SraP binds to this platelet
receptor.
3.1.2. Indirect interaction with GPIbα
Additional studies identified that bacterial interaction with platelets was abolished when
plasma was removed, suggestive of the need for a plasma protein in the interaction. Subse‐
quent studies identified that a number of bacteria bind vWf and bridge the bacteria to platelet
GPIbα. For example, S. aureus expresses protein A (SpA) on its surface which binds to
immobilised vWf under both static and shear based conditions which in turn bridges to platelet
GPIbα. Site directed mutagenesis demonstrated that all five domains of SpA (A-E) can bind
to the A1 domain of vWf with high affinity (low nM range) [47]. It is well established that
GPIbα binding vWf can cross link to another platelet via GPIbα which represents agglutination
rather than true platelet aggregation involving GPIIbIIIa and fibrinogen. Additional experi‐
ments are required to establish if the protein A-vWf interaction represents agglutination or
true aggregation. Helicobacter pylori is the main causative organism of peptic ulcers and have
been shown to induce platelet aggregation in vitro by binding to vWf which in turn bridges to
platelet GPIbα triggering an activating response. Blocking vWf or GPIbα with inhibitory
antibodies prevented the interaction. Patients lacking expression of GPIbα (Bernard Soulier
Syndrome) fail to aggregate in response to H. pylori [34]. To date the H. pylori component that
binds vWf has not yet been identified [48].
3.2. Glycoprotein IIbIIIa
3.2.1. Direct interaction with GPIIbIIIa
A number of different species of bacteria have been shown to bind directly to GPIIbIIIa.
Physiological ligands mediate attachment to GPIIbIIIa via a short amino acid sequence, RGD.
Consistent with this observation, several bacterial proteins have been identified to express an
RGD-like sequence in their cell wall proteins. The serine/aspartate (SD) repeat family of
proteins are among the most important cell wall components expressed on the surface of the
skin commensal Staphylococcus epidermidis. SdrG, also referred to as Fbe, is expressed on up to
91% of clinical S. epidermidis strains [49]. Protein analysis identified a potential RGD-like
sequence (643RTD) in the B-domain of the SdrG protein. Platelet adhesion to a purified
recombinant B-domain of SdrG was inhibited by using either a short synthetic peptide
containing the RGD sequence or the GPIIbIIIa antagonist tirofiban (which spans the RGD site),
suggesting that this sequence is responsible for directly interacting with GPIIbIIIa [50].
Under iron limited conditions S. aureus expresses a surface determinant called IsdB which also
contains an RGD-like sequence (248KYD) [51]. Surface plasmon resonance demonstrated that
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recombinant IsdB interacts directly with purified GPIIb/IIIa with high affinity with a dissoci‐
ation constant (KD) of 405±73.7nM. Platelet adhesion and aggregation was significantly
reduced following preincubation of platelets with the GPIIbIIIa antagonist tirofiban or an
inhibitory RGDS peptide mimetic. Furthermore, a strain defective in expression of IsdB also
failed to bind to GPIIbIIIa [51].
Streptococcus gordonii expresses a large molecular weight protein on its surface (397kDa)
designated platelet adherence protein A (PadA). Platelet adhesion to S. gordonii was inhibited
by the GPIIbIIIa antagonist abciximab or an inhibitory peptide mimetic, RGDS [52]. Platelets
adhering to immobilised S. gordonii or specific fragments of PadA underwent dramatic changes
in morphology as observed by fluorescent confocal microscopy. Rearrangement of the platelet
actin cytoskeleton led to filopodia and llamelipodia formation resulting in full platelet
spreading [53]. Proteomic analysis identified that PadA contains integrin recognition motifs
(383RGT and 484AGD) that may act as binding sites for GPIIbIIIa. Using site directed mutagenesis
the AGD or RGT sequence was replaced with a AAA. Platelet interaction with these mutants
demonstrated that platelet adhesion was unaffected however platelet spreading was signifi‐
cantly reduced. In addition, replacement of the RGT sequence to AAA (but not the AGD
sequence) significantly reduced granule secretion [54]. These results suggesting that there are
potentially multiple sequences on PadA responsible for specific platelet functions. The
sequence that is directly responsible for supporting platelet adhesion has currently not yet
been identified.
3.2.2. Indirect interaction with GPIIbIIIa
Both staphylococci and streptococci express a number of plasma protein binding proteins on
their surface. Probably the most common are fibrinogen binding proteins, often expressed at
different phase of bacterial growth. For example, S. aureus expresses clumping factor B (ClfB),
fibronectin binding protein A (FnBPA), fibronectin binding protein B (FnBPB) in the early stage
of growth (exponential phase) and clumping factor A (ClfA) in the late stage of growth
(stationary phase). S. epidermidis expresses a fibrinogen binding protein, SdrG, at the expo‐
nential phase of growth. Group A (Streptococcus pyogenes) and Group B (Streptococcus agalac‐
tiae) streptococcus also express fibrinogen binding proteins called M protein and FbsA,
respectively, in the exponential phase of growth.
The ligand binding sites of ClfA and ClfB have been mapped to residues 220 to 559 [55].
Interestingly the ligand binding sites of the two homologs are only 27% identical. In contrast
to ClfA which recognises the extreme C-terminus of the γ-chain of fibrinogen, ClfB recognises
the α-chain of fibrinogen [56, 57]. The FnBPA or FnBPB can bind either fibronectin or fibrino‐
gen. The N-terminal region of the fibronectin binding proteins (N1, N2 and N3) is structurally
and functionally similar to the clumping factors, however in place of the serine-aspartate repeat
region are tandemly repeated fibronectin-binding repeat domains. The FnBP’s bind fibrinogen
via the N1, N2 and N3 domains and fibronectin via the repeat domains (11 in FnBPA and 10
in FnBPB) [58]. SdrG (S. epidermidis) has the same structural organisation as the clumping
factors and bind directly to the beta-chain of the fibrinogen molecule with a Kd in the range
of 90-300nm [59, 60].
Platelet Interactions with Bacteria
http://dx.doi.org/10.5772/60531
69
Group A streptococci (Streptococcus pyogens) express more than 80 types of the highly virulent
factor, M-protein [61]. The fibrinogen binding motif differs between homologs of M-proteins,
suggesting that this domain might have evolved independently in different M-protein lineages
[62]. The exact binding site on fibrinogen that interacts with M-protein has not yet been defined,
however in inhibitory peptide mimetic RGDS, abolishes platelet aggregation, suggesting the
RGD site is involved [63]. Group B streptococcus (GBS) express three homologous proteins
termed FbsA, FbsB and FbsC (BsaB). While all of these proteins have all been shown to bind
fibrinogen to date only fsbA has been shown to be capable of binding fibrinogen and cross‐
linking to GPIIbIIIa [64]. Different GBS strains possess different numbers of repeat domains
in the FbsA protein thus accounting for the size heterogeneity of the protein. Studies have
demonstrated that a single repeat unit was capable of binding fibrinogen [65]. Although the
site on the fibrinogen molecule that binds to FsbA was not identified, an RGDS peptide
abolished the interaction suggesting that this motif on fibrinogen is critical [64].
A common observation is beginning to unfold in the light of all the fibrinogen binding proteins
expressed on bacteria. Results demonstrate that where a bacterial protein binds fibrinogen and
crosslinks to platelet GPIIbIIIa it is usually not enough to trigger an activating signal in the
platelet and usually requires a co-stimulus In all cases outlined above the key co-stimulus is
provided by the bacteria binding IgG and cross linking to its reciprocal receptor on platelets,
FcγRIIa.
3.3. FcγRIIA
3.3.1. Direct interaction with FcγRIIA
Currently there are no reports of a bacterial protein binding directly to FcγRIIa on platelets,
however there are a number of reports of an indirect interaction where bacterial proteins use
IgG to cross link to platelet FcγRIIA.
3.3.2. Indirect interaction with FcγRIIA
FcγRIIA is fast becoming the most important receptor in platelet bacterial interactions as it has
been shown to inhibit all bacterial induced platelet activation including those triggered by S.
aureus, S. epidermidis, S. sanguinis, S. gordonii, Streptococcus pneumonia, Streptococcus oralis, H.
pylori and S. pyogenes [30, 33, 34, 36, 50, 53, 66-70]. A key observation is that IgG is required for
all of these bacteria to induce platelet aggregation, however antibody alone was not enough
to trigger aggregation / activation of platelets. In all cases engagement of another platelet
receptor was required such as GPIIbIIIa, GPIbα, or Toll Like Receptors (TLR’s). These obser‐
vations suggest that FcγRIIa requires receptor clustering in order to trigger platelet activation
[69]. Indeed FcγRIIa has been shown to be physically associated with GPIIbIIIa and GPIbα
and therefore plays an important role in their respective signalling in an IgG-independent
manner [71].
The Non-Thrombotic Role of Platelets in Health and Disease70
Platelet receptor Bacteria & protein Bridging protein Reference
GPIbα S. gordonii GspB/Hsa Direct 42,43,44
S. sanguinis SrpA Direct 30,94
S. aureus SraP ? 46
S. aureus SpA vWf 47
H. pylori [unidenified] vWf 48
GPIIbIIIa S. epidermidis SdrG Direct 49,50
S. aureus IsdB Direct 51
S. gordonii PadA Direct 52,53,54
S. aureus ClfA Fibrinogen 55,56
S. aureus ClfB Fibrinogen 57
S. aureus FnbpA/B Fibronectin 58
S. epidermidis SdrG Fibrinogen 59,60
S. pyogenes M1 Fibrinogen 62,63
S. agalactiae Fbs Fibrinogen 64,65
FcγRIIa S. aureus FnbpA/B IgG 33
S. aurues ClfA IgG 36
S. aureus ClfB IgG 72
S. epidermidis SdrG IgG 50
H. pylori [unidentified] IgG 34
P. gingivalis [unidentified] IgG 73
gC1q-R/P32 S. aureus SpA direct 74,75
S. aureus ClfA ? 32, 36
S. aureus ClfB ? 32,72
S. sanguinis [unidentified] ? 38,77
TLR2 S. pneumoniae [unidentified] direct 67
P. gingivalis [unidentified] direct 79
Table 1. Summary of interactions between bacteria and platelets. Bacteria can either interact with platelets directly or
indirectly using a bridging protein, thus triggering activation. ClfA; clumping factor A, FnbpA; fibronectin binding
protein A, SpA; protein A, PadA; platelet adhesion protein A, IsdB; iron-regulated surface determinant B, SdrG; Serine
aspartate repeat G, Hsa; haemaglutinin salivary antigen, GspB; glycosylated spretococcal protein B, SrpA; serine rich
protein A, IgG; immunoglobulin G, vWf; vonWillebrand Factor, C1q; complement 1q, GP; glycoprotein, TLR; Toll like
receptor
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Platelet receptor Bacteria Bacterial toxin Reference
TLR4 E. coli LPS 81,82,83,84
? S. epidermidis LTA 85,86,87,88
? P. gingivalis Gingipains 39,89
Glycospingolipids E.coli Verotoxin 41,90
? S. aureus α-toxin 91,92
Table 2. Summary of interactions between platelets and bacterial toxins. LPS; Lipopolysaccharide, LTA; Lipoteichoic
acid
S. aureus  and S. epidermidis  induce platelet aggregation in an FcγRIIa dependent manner.
S. aureus fails to induce platelet aggregation in the absence of plasma proteins. Addition of
IgG alone is not enough to trigger aggregation induced by S. aureus, however addition of
fibrinogen/fibronectin and IgG combined induces full aggregation [33, 36, 72]. Similarly S.
epidermidis  SdrG also induces  platelet  aggregation however  requires  concomitant  bind‐
ing of fibrinogen and IgG to the A-domain of SdrG and an unidentified cell wall compo‐
nent of H. pylori requires concomitant binding of vWf and IgG which crosslinks to GPIbα
and FcγRIIa [34, 50].
All published reports of streptococcal induced platelet aggregation demonstrate their ability
to induce platelet aggregation in an FcγRIIa dependent manner. Early reports suggested that
streptococci could induce platelet aggregation in the absence of plasma proteins. However
regardless of this, blocking FcγRIIa with a monoclonal antibody still abolished aggregation
[30], suggesting that FcγRIIa may be playing a role in signal amplification. This observation is
analogous to the role of FcγRIIa in promoting cell signalling/amplification through various
platelets receptors such as GPIIbIIIa and GPIbα. Another oral bacteria, S. oralis on the other
hand failed to induce platelet aggregation in gel filtered platelets [68]. The addition of plasma
concentrations of fibrinogen to the gel filtered platelets failed to restore aggregation however
addition of plasma concentrations of purified IgG fully restored platelet aggregation. More
recently, Arman et al, demonstrated that S. sanguinis, S. gordonii but not S. pneumoniae require
IgG’s to induce platelet aggregation [69]. The site that IgG binds to was not identified in this
study.
Oral bacteria, Porphomonas gingivalis expresses a surface protein called hgp44 which induces
platelet aggregation in an FcγRIIA dependent manner [73]. The authors demonstrated that
IgG was critical for the interaction. Preincubation of platelets with an anti-FcγRIIa antibody
abolished P. gingivalis induced platelet aggregation. Furthermore, depletion of IgG from
plasma also completely prevented aggregation. Interestingly recombinant hgp44 failed to
induce platelet aggregation suggesting that hgp44 may be dependent on another P. gingiva‐
lis protein binding to platelets in order to crosslink receptors to trigger a signal that results in
platelet aggregation.
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3.4. gC1q-R/P33
3.4.1. Direct interaction with gC1q-R/P33
S. aureus SpA has been shown to be capable of binding directly to full length recombinant
gC1qR (amino acids 1-282). Under resting conditions there is a low level of gC1qR expression
on platelets, however upon activation expression levels significantly rises [74]. The latter
suggests that another interaction between S. aureus and the platelet is required in order to
express high levels of the receptor on the platelet surface. Binding was inhibited by both
recombinant gC1qR and soluble purified protein A, however complement proteins did not
appear to be required as the binding interaction occurs in the absence of complement proteins.
Deletion of the C1q binding domain (amino acids 74-95) on the recombinant gC1qR resulted
in loss of C1q binding but not S. aureus SpA suggesting that the SpA binding site is likely to
reside outside of this domain [75].
3.4.2. Indirect interaction
Complement is part of the immune system that augments the opsonisation of bacteria by
antibodies which in turn facilitates phagocytosis. There are three main pathways that lead to
complement activation; the classical pathway can be triggered by antigen-antibody complexes;
the alternative pathway can be triggered by binding specific complement proteins binding to
the bacterial surface and finally the lectin pathway can be triggered by mannose binding
protein binding the bacterial surface [76]. The lag time to platelet aggregation in response to
S. aureus (mediated by ClfA or ClfB) is 2-4 mins and required the binding of fibrinogen and
IgG to their respective receptors on platelets in order to trigger full activation and aggregation
[32]. Subsequent studies on these interactions discovered that by deleting the fibrinogen
binding domain on S. aureus ClfA (ClfA-PY) or ClfB (Q235A) it significantly extended the lag
time to aggregation (12-15 mins) suggestive of a second much slower interaction [36, 72].
Heating plasma to destroy proteins abolished platelet activation and aggregation by both ClfA-
PY and ClfB-Q235A. Further studies using zymosan, which removes complement proteins
from plasma, also inhibited platelet activation and aggregation by both ClfA-PY and ClfB-
Q235A. These studies suggested that complement played a key role in the second much slower
interaction that resulted in platelet activation/aggregation. The receptor on platelets that binds
bacteria coated complement proteins has not been identified yet.
The lag time to platelet  aggregation varies with different strains of  S.  sanguinis  [77],  for
example S. sanguinis can induce platelet aggregation with a lag time of 2-4 minutes or 12-15
minutes. The long lag time is indicative of the time taken for complement assembly [38].
Inactivation of complement by cobra venom or heat treatment abolished aggregation [38].
It is not known precisely how complement activation triggers platelet activation but it is
possible that there is a threshold of bacterial-platelet interactions (capable of inducing strong
or weak signals) which must be surpassed before triggering platelet aggregation however
this remains to be investigated.
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3.5. Toll like receptor 2
3.5.1. Direct interaction with TLR2
Streptococcus pneumoniae is a major pathogen usually found colonising the upper respiratory
tract and nasopharynx. Following intense inflammatory response of the lungs the bacteria can
gain entry to the bloodstream. S. pneumonia has been shown to bind induce platelet aggregation
and dense granule secretion [67]. Preincubation of platelets with an inhibitory TLR2 antibody
abolished platelet aggregation and dense granule secretion induced by S. pneumoniae. Both
aggregation and dense granule secretion was dependent on FcγRIIa however antibody was
not required for either to take place, further suggesting that this receptor plays a role in signal
amplification possibly through recruitment of adapter proteins to initiate signaling. Interest‐
ingly stimulation of TLR2 by S. pneumoniae resulted in the activation of the PI3 kinase pathway
[67]. PI3-kinase is typically a negative regulator of TLR2-dependent responses in several
immune cells. However, in platelets many studies demonstrate that PI3-kinase acts as a
positive regulator in various platelet functions such as adhesion, aggregation and spreading
[78]. Therefore it appears that PI3 kinase is a positive regulator of S. pneumoniae-induced
platelet aggregation. Oral bacteria, Porphyromonas gingivalis induced platelet-neutrophil
aggregates in a TLR2 dependent manner. This response was significantly reduced in TLR2
deficient mice, highlighting the importance of this receptor in the platelet recognition of P.
gingivalis [79]. Consistent with previous observations the authors also demonstrated that PI3
kinase was critically important in the signalling response mediated downstream of TLR2.
4. Secreted products
Lipopolysaccharide (LPS) is shed from the cell wall of gram negative bacteria into the local
milieu and interacts with Toll-like receptors (TLR) on immune cells [80]. Escherichia coli LPS
was shown to bind to and mediate activation of platelets in a TLR4-dependent manner [81]
and to enhance platelet secretion of cytokines [82]. Chicken thymocytes were also shown to
express TLR4 receptor and to become activated by LPS [83]. There seems to be variation in the
ability of different types of LPS to bind to platelets and LPS from E. coli O157 appears to be the
most potent [81]. Although LPS was found to bind to TLR4 on platelets, there is little evidence
to suggest that binding leads to platelet activation. LPS bound platelets had increased affinity
for neutrophils and only LPS-treated platelets were capable of inducing neutrophil activation
[84]. LPS injected into wildtype mice induced thrombocytopenia that was neutrophil-depend‐
ent [13]. Thus, current understanding is that LPS binds to platelet TLR4 but does not generate
an activation signal, at least not one than leads to platelet aggregation. However, LPS appears
to prime the platelets allowing them to bind to and activate neutrophils.
In contrast Lipoteichoic acid (LTA) is secreted by Gram-positive bacteria. LTA binds to
platelets and inhibits platelet aggregation by collagen [85]. LTA also supports platelet adhesion
to S. epidermidis [86]. Some studies suggested that the anti-platelet effect of LTA was due to
conformational changes in the membrane [87] and an increase in cAMP levels [88].
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In a manner similar to thrombin activation of the Protease Activated Receptors on the platelet
surface, Porphyromonas gingivalis secretes gingipains which are proteases that can directly
activate platelets [39, 89]. Shiga-like toxin (verotoxin) is secreted by E. coli and triggers platelet
aggregation [90] by binding to glycosphingolipid receptors on the platelet surface [41]. α-toxin
is a pore forming toxin produced by S. aureus which is responsible for haemolysis. It also leads
to platelet activation [91] leading to the assembly of the pro-thrombinase complex on the
platelet surface [92].
5. Animal studies versus clinically relevant models of infection
There are many reports in the literature investigating the interaction between bacteria and
platelets in vivo. Translating animal studies to human disease is becoming increasingly
difficult, especially with the identification that FcγRIIA is a key receptor involved in signal
amplification in human platelets [69]. FcγRIIa is unique to higher primates and therefore calls
into question the validity of using mouse, rat or rabbit animal models for studying platelet-
bacterial interactions [93], as they do not express FcγRIIa. Although mouse, rat and rabbit
platelets do aggregate in response to bacteria in vivo, the mechanism through which they signal
must be different. Transgenic mice expressing human FcγRIIa are available commercially
which can overcome this problem.
One potential possibility to overcome this problem is to develop a more clinically relevant model
of infection using physiological conditions with human platelets. Using a parallel flow chamber
with human platelets and shear conditions experienced under human physiological condi‐
tions a number of key interactions were observed. Under fluid shear conditions, human platelets
rolled on immobilised S. sanguinis and S. gordonii at low shear rates (50s-1) followed by firm
adhesion [42, 94]. This rolling behaviour was similar to the interaction between platelet GPIbα
and vWf. Of key interest is that platelet rolling on vWf occurs under high shear conditions
(>1000s-1) where the platelet rolling on bacteria occurs under low shear conditions (50s-1).
Deletion of cell wall proteins S. sanguinis SrpA or S. gordonii Hsa abolished the rolling behav‐
iour suggesting that these proteins must be in a conformation for direct interaction with platelet
GPIbα under low shear conditions [42, 94]. Platelets rolled, adhered and formed micro thrombi
on immobilised S. oralis at shear rates of 50s-1 to 800s-1. This interaction was also dependent on
GPIbα as determined by anti-GPIbα antibodies and blood from a Bernard Soulier patient.
Aggregate formation was dependent on S. oralis binding IgG, which cross-links to platelet
FcγRIIa. This interaction also led to phosphorylation of the ITAM domain on FcγRIIa, result‐
ing in dense granule secretion and amplification through the ADP receptor [68].
S. pyogenes interacts with platelets under high shear conditions. The major cell wall component
M-protein was found to bind IgG and fibrinogen which cross link to FcγRIIa and GPIIbIIIa
respectively to trigger thrombus formation [95]. S. aureus also triggered thrombus formation
in the presence of human whole blood under high shear conditions (800s-1). These studies
identified that deletion of major cell wall protein ClfA but not other cell wall proteins (FnBP’s,
SpA or SdrC) completely abolished thrombus formation. Thrombus formation was dependent
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on fibrinogen and IgG binding to platelets in order to trigger thrombus formation. Subsequent
studies demonstrated that S. aureus ClfA bound IgG and fibrinogen crosslinked to FcγRIIa and
GPIIbIIIa respectively thus triggering thrombus formation. Of particular interest is that S.
aureus failed to interact with platelets under low shear [66].
6. Conclusion
Although the field of platelet bacterial interactions is in its infancy, significant advances have
been made in identifying some of the molecular mechanisms. Through learning about these
interactions it has provided strong evidence that platelets may indeed be acting as primitive
immune cells. However a lot more research is required to gain a better understanding of the
exact role platelets play in in the process. For example, by adhering, aggregating, spreading
or forming a thrombus on the bacteria are the platelets trying to restrict spread of infection
and then by releasing their granular contents orchestrate or control the immune response to
the infection by recruiting defined numbers of leukocytes. Alternatively is it a clever move by
the bacteria who coat themselves in non-professional immune cells (platelets) and therefore
rendering themselves safe from attack from professional immune cells (leukocytes) and
antibiotics, which cannot penetrate the platelet encapsulation to kill the bacteria thus allowing
them to grow and divide in a safe environment.
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